KRAS and neoplasm: Here, we investigated the tumor cell-intrinsic contribution of EGFR in KRAS<sup>G12D</sup> tumors by establishing murine CRC organoids with key CRC mutations (KRAS, APC, TP53) and inducible EGFR deletion.